Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 17/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516212 | 1.00 | SIRT1 (0.52) | SIRT1SIRT2TDP1SIRT3MEN1 | |
| SCHEMBL26938748 | 0.90 | KMT2A (0.41) | SIRT1SIRT2TDP1SIRT3MEN1 | |
| SCHEMBL26938829 | 0.80 | SIRT1 (0.65) | SIRT1SIRT2TDP1SIRT3 | |
| SCHEMBL24378125 | 0.80 | SIRT1 (0.65) | SIRT1SIRT2TDP1SIRT3 | |
| SCHEMBL24378118 | 0.80 | SIRT1 (0.65) | SIRT1SIRT2TDP1SIRT3 | |
| SCHEMBL24378008 | 0.78 | ALDH1A1 (0.48) | SIRT1SIRT2SIRT3KMT2A | |
| SCHEMBL29516344 | 0.78 | ALDH1A1 (0.48) | SIRT1SIRT2SIRT3KMT2A | |
| SCHEMBL29516124 | 0.78 | TP53 (0.49) | SIRT1MEN1KMT2A | |
| SCHEMBL24378122 | 0.78 | TP53 (0.49) | SIRT1MEN1KMT2A | |
| SCHEMBL26939793 | 0.76 | KMT2A (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-116323571-A | Covalent inhibitors of Creatine Kinase (CK) and their use for the treatment and prevention of cancer | 丹娜法伯癌症研究院 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | SIRT1 935/4885SIRT2 1211/4885TDP1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.